A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 Trial
This in-depth description of a Phase 1 clinical trial initiated in April 2020 provides strong initial evidence for the safety and efficacy of a therapeutic vaccine against fibrolamellar carcinoma (FLC). The vaccine was given in combination with two immune checkpoint inhibitors (ICIs) already approved for use against many cancers. Published in the prestigious journal Nature …